Home > Insider Trading > Filing (0001179110-22-000693)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1709401	Rubius Therapeutics Inc.	RUBY	Biological Products, (No Disgnostic Substances) (2836)	042688109

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1800952	A. Laurence Turka	C/O Rubius Therapeutics, Inc. 399 Binney Street, Suite 300 Cambridge MA 02139	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-01-29	7,438	$0.00	7,438	No	4	M	Direct
Common Stock	Disposition	2022-02-01	2,517	$6.57	4,921	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2022-01-29	7,438	$0.00	7,438	$0.00
Common Stock	Stock Option (Right to Buy)	Acquisiton	2022-01-31	143,750	$0.00	143,750	$6.75
Common Stock	Restricted Stock Units	Acquisiton	2022-01-31	34,500	$0.00	34,500	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
22,312		No	4	M	Direct
143,750	2032-01-30	No	4	A	Direct
34,500		No	4	A	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.70, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022.
25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.
The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.